Opinion|Videos|May 2, 2024
Multidisciplinary Care for Patients with CRC
Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Read a refresh of GI cancer FDA news from August 2026, including the approval of a RAS(ON) inhibitor in metastatic pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
2
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
3
AUA Releases Guideline Amendment for NMIBC
4
Five Under 5: Top Oncology Videos for the Week of 9/27
5